Clene's Neurogenerative Candidate Shows Potential For Improved Long-Term Survival

Clene Inc. CLNN released long-term follow-up data for patients treated with CNM-Au8 30mg for up to 133 weeks in the HEALEY ALS Platform Trial

These post hoc results showed significantly improved survival with a 49% decreased risk of death for the covariate risk-adjusted analyses as compared to the largest U.S. clinical database of previous amyotrophic lateral sclerosis (ALS) trials (PRO-ACT).

ALS is characterized by progressive degeneration of nerve cells in the spinal cord and brain.

In a pooled analysis of the HEALEY ALS Platform Trial and the RESCUE-ALS Trial, participants originally randomized to CNM-Au8 30mg (n=82) demonstrated a statistically significant 59% decreased risk of death compared to PRO-ACT matched placebo patients through long-term follow-up.

No serious adverse events have been assessed as related to CNM-Au8 treatment; adverse events observed with CNM-Au8 have been characterized as transient and predominantly mild-to-moderate in severity.

In June, Clene reported new data demonstrating a statistically significant reduction of plasma neurofilament light chain (NfL) levels for CNM-Au8 treated participants compared to placebo after 24 weeks in the HEALEY ALS Platform Trial.

CNM-Au8 treatment demonstrated significantly reduced plasma neurofilament light chain levels compared to the placebo at 24 weeks (p=0.04).

The 24-month long-term data cut from the Phase 2 RESCUE-ALS ongoing open-label extension (OLE) showed a significant median survival benefit of 19.3 months and a 52% decreased risk of ALS clinical worsening events with CNM-Au8 treatment.

Price Action: CLNN shares were up 0.22% at $0.46 on the last check Monday.

Read Next: Vapotherm's Asthma Therapy More Effective Than Standard Oxygen Therapy In Kids

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareMoversTrading IdeasGeneralBriefspharmaceuticalsprevious amyotrophic lateral sclerosis
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!